Literature DB >> 28949786

Extracellular vesicles as an efficient nanoplatform for the delivery of therapeutics.

Chao Liu1, Haiyan Gao1, Peng Lv1, Jingyi Liu1, Gang Liu1.   

Abstract

Extracellular vesicles (EVs) are membrane-derived vesicles that are enriched with RNAs, proteins and other functional molecules. We exploit the unique physical properties of EVs as a promising and advantageous nanoplatform for the delivery of therapeutic drugs and genetic materials. Early successes in the discovery of various disease-related characteristics of EVs have driven a new wave of innovation in developing nanoscale drug-delivery systems (DDSs). Nevertheless, there are several issues that need to be considered during the development of these alternative DDSs, such as standardized isolation and preservation methods, efficient drug encapsulation, mechanisms of drug release and so on. In this mini-review, we summarize the current status and progress of EV-based DDSs as an efficient nanoplatform for therapeutics delivery, followed by a discussion on their challenges and future prospects for clinical translation and applications.

Keywords:  cancer; clinical translation; drug delivery system; extracellular vesicles

Mesh:

Substances:

Year:  2017        PMID: 28949786      PMCID: PMC5703411          DOI: 10.1080/21645515.2017.1363935

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  121 in total

Review 1.  Nanomedicine: An unresolved regulatory issue.

Authors:  Vivian S W Chan
Journal:  Regul Toxicol Pharmacol       Date:  2006-11-01       Impact factor: 3.271

2.  Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an interleukin 8-dependent survival of leukemia cells.

Authors:  Chiara Corrado; Stefania Raimondo; Laura Saieva; Anna Maria Flugy; Giacomo De Leo; Riccardo Alessandro
Journal:  Cancer Lett       Date:  2014-03-18       Impact factor: 8.679

Review 3.  Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine.

Authors:  Stefano Fais; Lorraine O'Driscoll; Francesc E Borras; Edit Buzas; Giovanni Camussi; Francesco Cappello; Joana Carvalho; Anabela Cordeiro da Silva; Hernando Del Portillo; Samir El Andaloussi; Tanja Ficko Trček; Roberto Furlan; An Hendrix; Ihsan Gursel; Veronika Kralj-Iglic; Bertrand Kaeffer; Maja Kosanovic; Marilena E Lekka; Georg Lipps; Mariantonia Logozzi; Antonio Marcilla; Marei Sammar; Alicia Llorente; Irina Nazarenko; Carla Oliveira; Gabriella Pocsfalvi; Lawrence Rajendran; Graça Raposo; Eva Rohde; Pia Siljander; Guillaume van Niel; M Helena Vasconcelos; María Yáñez-Mó; Marjo L Yliperttula; Natasa Zarovni; Apolonija Bedina Zavec; Bernd Giebel
Journal:  ACS Nano       Date:  2016-03-15       Impact factor: 15.881

4.  Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes).

Authors:  R M Johnstone; M Adam; J R Hammond; L Orr; C Turbide
Journal:  J Biol Chem       Date:  1987-07-05       Impact factor: 5.157

Review 5.  Exosomal tumor-suppressive microRNAs as novel cancer therapy: "exocure" is another choice for cancer treatment.

Authors:  Nobuyoshi Kosaka; Fumitaka Takeshita; Yusuke Yoshioka; Keitaro Hagiwara; Takeshi Katsuda; Makiko Ono; Takahiro Ochiya
Journal:  Adv Drug Deliv Rev       Date:  2012-07-25       Impact factor: 15.470

6.  Thymus exosomes-like particles induce regulatory T cells.

Authors:  Gui-Jun Wang; Yuelong Liu; Aijian Qin; Spandan V Shah; Zhong-bin Deng; Xiaoyu Xiang; Ziqiang Cheng; Cunren Liu; Jianhua Wang; Liming Zhang; William E Grizzle; Huang-Ge Zhang
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

7.  A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy.

Authors:  Yanhua Tian; Suping Li; Jian Song; Tianjiao Ji; Motao Zhu; Gregory J Anderson; Jingyan Wei; Guangjun Nie
Journal:  Biomaterials       Date:  2013-12-15       Impact factor: 12.479

8.  Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.

Authors:  Synne Sandbu; Berit Feiring; Philipp Oster; Oddveig S Helland; Hilde S W Bakke; Lisbeth M Naess; Audun Aase; Ingeborg S Aaberge; Anne-Cathrine Kristoffersen; Kjersti M Rydland; Sandrine Tilman; Hanne Nøkleby; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2007-07-18

9.  Microparticles harboring Sonic Hedgehog promote angiogenesis through the upregulation of adhesion proteins and proangiogenic factors.

Authors:  Raffaella Soleti; Tarek Benameur; Chiara Porro; Maria Antonietta Panaro; Ramaroson Andriantsitohaina; Maria Carmen Martínez
Journal:  Carcinogenesis       Date:  2009-01-23       Impact factor: 4.944

10.  Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant.

Authors:  Jonathan R Aspe; Carlos J Diaz Osterman; Jessica M S Jutzy; Simone Deshields; Sonia Whang; Nathan R Wall
Journal:  J Extracell Vesicles       Date:  2014-02-17
View more
  4 in total

1.  Genetically Engineered Cellular Membrane Vesicles as Tailorable Shells for Therapeutics.

Authors:  En Ren; Chao Liu; Peng Lv; Junqing Wang; Gang Liu
Journal:  Adv Sci (Weinh)       Date:  2021-09-08       Impact factor: 16.806

Review 2.  The Emerging Role of Exosomes in Diagnosis, Prognosis, and Therapy in Head and Neck Cancer.

Authors:  Linda Hofmann; Sonja Ludwig; Julius M Vahl; Cornelia Brunner; Thomas K Hoffmann; Marie-Nicole Theodoraki
Journal:  Int J Mol Sci       Date:  2020-06-06       Impact factor: 5.923

Review 3.  EVs and Bioengineering: From Cellular Products to Engineered Nanomachines.

Authors:  Simona Villata; Marta Canta; Valentina Cauda
Journal:  Int J Mol Sci       Date:  2020-08-22       Impact factor: 5.923

4.  The therapeutic potential of exosomal miR-22 for cervical cancer radiotherapy.

Authors:  Hiromi Konishi; Masami Hayashi; Kohei Taniguchi; Mayumi Nakamura; Yuki Kuranaga; Yuko Ito; Yoichi Kondo; Hiroshi Sasaki; Yoshito Terai; Yukihiro Akao; Masahide Ohmichi
Journal:  Cancer Biol Ther       Date:  2020-11-16       Impact factor: 4.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.